COVID-19 vaccine development part 26

Posted in Tak Berkategori | Leave a comment

COVID-19 vaccine development part 25

Posted in Tak Berkategori | Leave a comment

COVID-19 vaccine development part 24

Posted in Tak Berkategori | Leave a comment

COVID-19 vaccine development part 23

Posted in Tak Berkategori | Leave a comment

COVID-19 vaccine development part 22

Posted in Tak Berkategori | Leave a comment

COVID-19 vaccine development part 21

Resources on COVID-19 vaccines development:

  • WHO target product profile for COVID-19 vaccine
  • Vaccine landscape
  • Solidarity vaccine trial
  • Access to COVID tools (ACT) Accelerator
  • COVAX facility (WHO) Covax explained (GAVI) COPVAX (CEPI)
  • WHO guidance on ethnics of vaccine allocation
Posted in Tak Berkategori | Leave a comment

COVID-19 vaccine development part 20

Working together to deliver vaccine to all countries:

  • The Access to Covid-19 Tools (ACT) Accelerator was launched in April 2020 to speed up development and delivery to countries of diagnostics, treatments and vaccines. It includes a health systems connector to support delivery of these resources to countries.
  • WHO developed a framework for equitable  and affordable access to safe and effective vaccines.
  • The COVAX facility is an umbrella mechanism through which demand and resources are pooled to support procurement of, and equitable access to, COVID-19 vaccines.
  • The ACT Accelerator aims to deliver two billion vaccine doses for global needs by the end of 2021.
  • Vaccine allocation will be driven by public health needs for priority groups, which may represent about 20% of the population, in the first year.
  • Countries will be asked to develop vaccination plans.
  • WHO recommends front-line personnel (such as health workers) and seniors be the first priority to receive vaccine
Posted in Tak Berkategori | Leave a comment

COVID-19 vaccine development part 19

WHO Solidarity vaccine trial (Achieving rapid progress towards global objectives) :

  • Evaluating several different candidate vaccines:

      Increasing the likelihood of finding several effective vaccines

  • Expenditiously enrolling people at sites with high rates of COVID-19:

      Rapid accumulation of data to support rigorous evaluation

  • Eliminating inefficiency of design and conduct of separate trials:

     Results within 3-6 months after each vaccine is ready for inclusion

  • International collaboration and country commitment:

      Fosters international deployment with equity of access

Posted in Tak Berkategori | Leave a comment

COVID-19 vaccine development part 18

WHO COVID-19 Solidarity vaccine trial :

  • On 28 May 2020, WHO announced the launch of a coordinated international, concurrent randomized controlled Phase III trial of different vaccine candidates
  • A trial in several sites at once will help speed evaluation and ensure that vaccines will have been tested in different populations
  • The trial aims to enroll more than 280.000 from at least 470 different sites in 34 countries
  • Local involvement will help to identify trial sites with high COVID-19 transmission to ensure community engagement
Posted in Tak Berkategori | Leave a comment

COVID-19 vaccine development part 17

COVID-19 vaccine candidates in Phase III trials :

  • As of 02 October 2020 there are 42 COVID-19 candidate vaccines in clinical evaluation of which 10 in phase III trials
  • There are another 151 candidate vaccines in preclinical evaluation
  • Phase III trials usually require 30.000 or more participants
  • All top candidate vaccines are for intra-muscular injection
  • Most are designed for a two-dose schedule 
Posted in Tak Berkategori | Leave a comment